The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study.
Economic burden
Health policy
Healthcare costs
Iran
Prostate cancer
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
26
05
2024
accepted:
23
08
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
This study aims to assess the economic burden of prostate cancer in Iran by analyzing direct medical costs, direct non-medical costs, and indirect costs. We conducted a cross-sectional cost-of-illness study in Khorramabad, located in western Iran, during 2023, using a prevalence-based, bottom-up approach. Data were collected from 285 prostate cancer patients using questionnaires, interviews, and patient records. Our study estimated the economic burden of prostate cancer at $744,990. Direct medical costs accounted for 63.50% of this, totaling $153,330, with therapy being the largest component. Direct non-medical costs were $62,130, and indirect costs from productivity losses were $209,760. The calculated overall cost per patient was $2,614.88. Extrapolating from the 2021 Global Burden of Disease data, which reported approximately 83,000 prostate cancer patients in Iran, the national economic burden is estimated at $217,034,040. This substantial burden highlights the need for improved insurance coverage and early detection. The findings suggest that policymakers and healthcare providers in Iran should develop standardized cost analysis methods and enhance financial protection to alleviate economic strain and improve healthcare outcomes and sustainability.
Identifiants
pubmed: 39289778
doi: 10.1186/s13104-024-06913-6
pii: 10.1186/s13104-024-06913-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
268Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.
pubmed: 35252092
pmcid: 8888523
doi: 10.3389/fpubh.2022.811044
Teoh JYC, Hirai HW, Ho JMW, Chan FCH, Tsoi KKF, Ng CF. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS ONE. 2019;14(10):e0221775.
pubmed: 31647819
pmcid: 6812812
doi: 10.1371/journal.pone.0221775
Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138(6):1388–400.
pubmed: 26488767
doi: 10.1002/ijc.29894
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate Cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.
pubmed: 31493960
doi: 10.1016/j.eururo.2019.08.005
Alinezhad F, Khalili F, Zare H, Lu C, Mahmoudi Z, Yousefi M. Financial burden of prostate cancer in the Iranian population: a cost of illness and financial risk protection analysis. Cost Eff Resour Alloc. 2023;21(1):84.
pubmed: 37932767
pmcid: 10629147
doi: 10.1186/s12962-023-00493-1
Mojahedian MM, Toroski M, Keshavarz K, Aghili M, Zeyghami S, Nikfar S. Estimating the cost of illness of prostate Cancer in Iran. Clin Ther. 2019;41(1):50–8.
pubmed: 30545740
doi: 10.1016/j.clinthera.2018.11.001
Rasouli MA, Moradi G, Zareie B, Sofimajidpour H, Tozandehjani S, Zafari H, et al. Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011–2018). BMC Cancer. 2021;21(1):1314.
pubmed: 34876069
pmcid: 8653556
doi: 10.1186/s12885-021-09078-8
Farabi H, Moradi N, Ahmadzadeh A, Aghamir SMK, Mohammadi A, Rezapour A. A cost-benefit analysis of mass prostate cancer screening. Cost Eff Resour Alloc. 2024;22(1):37.
pubmed: 38705990
pmcid: 11071254
doi: 10.1186/s12962-024-00553-0
Cantarero-Prieto D, Lera J, Lanza-Leon P, Barreda-Gutierrez M, Guillem-Porta V, Castelo-Branco L, et al. The Economic Burden of localized prostate Cancer and insights derived from cost-effectiveness studies of the different treatments. Cancers (Basel). 2022;14(17):4088.
pubmed: 36077625
doi: 10.3390/cancers14174088
Gustavsen G, Gullet L, Cole D, Lewine N, Bishoff JT. Economic burden of illness associated with localized prostate cancer in the United States. Future Oncol. 2020;16(1):4265–77.
pubmed: 31802704
doi: 10.2217/fon-2019-0639
Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat. 2009;16(1):53–63.
pubmed: 19192158
doi: 10.1111/j.1365-2893.2008.01042.x
Yong C, Onukwugha E, Mullins CD. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol. 2014;26(3):274–83.
pubmed: 24626126
doi: 10.1097/CCO.0000000000000071
Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–36.
pubmed: 22583452
doi: 10.1016/j.jval.2011.12.012
Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008;11(5):878–85.
pubmed: 18494749
doi: 10.1111/j.1524-4733.2008.00327.x
Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int. 2010;105(1):49–56.
pubmed: 20132102
doi: 10.1111/j.1464-410X.2009.08716.x
Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis. 2010;13(3):278–84.
pubmed: 20212521
doi: 10.1038/pcan.2010.5
Ngcamphalala C, Östensson E, Ginindza TG. The economic burden of prostate cancer in Eswatini. BMC Health Serv Res. 2022;22(1):483.
pubmed: 35410213
pmcid: 9004055
doi: 10.1186/s12913-022-07817-6